.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AA15_Balugrastim.Balugrastim .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AA15_Balugrastim.Balugrastim| name: | Balugrastim |
| ATC code: | L03AA15 | route: | subcutaneous |
| n-compartments | 1 |
Balugrastim is a long-acting recombinant granulocyte colony-stimulating factor (G-CSF) approved in some countries for the prevention of chemotherapy-induced neutropenia. It is a fusion protein of G-CSF and human serum albumin, designed for enhanced half-life and reduced dosing frequency, but is not widely available or approved in all regions.
Pharmacokinetic parameters estimated based on class characteristics and published clinical summaries for adult cancer patients receiving chemotherapy. Published studies directly reporting compartmental PK modeling data are not available.
Avisar, N, et al., & Pukac, L (2015). First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. Cancer chemotherapy and pharmacology 75(5) 929–939. DOI:10.1007/s00280-015-2703-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25740691